The Cell Therapy stream explores the critical challenges facing the manufacture, analysis and quality of cell-based therapies across clinical and commercial development. Featuring two back-to-back conferences, Cell Therapy CMC and Analytics, and Cell Therapy Manufacturing, topics include product and process characterization, CMC strategies, decentralized manufacturing, autologous and allogeneic manufacturing strategies, automation, the role of AI, scale-up and supply of CAR Ts and next-generation cell therapies such as NK cells, TILs, iPSCs, gamma deltas, and TCR-based therapies. 

Conferences Include:

KEYNOTE & FEATURED PRESENTATIONS

USP's Evolving Position on the Use of Rapid Microbial Methods for the Detection of Microbiological Contamination
Huiping Tu, PhD, Senior Principal Scientist, Microbiology, Global Biologics, USP

Developing First-in-Class Allogeneic off-the-Shelf TCR-T
Zhimei Du, PhD, CSO, BlueSphere Bio

Considerations for Process Development (CAR T Drug Product and Lentiviral Vector) in Autologous Cell Therapy for Commercial Manufacturing
Ravi Bhatia, Scientific Director, Cell Technology, Johnson & Johnson Pharmaceutical R&D

Visible Particles within Cell Therapies
Swapnil K Pansare, Director, MSA&T, AstraZeneca